Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF inhibition has improved overall survival in patients with BRAF mutant melanoma, but this is associated with a range of known and predictable cutaneous side effects, including squamous cell carcinomas associated with RAS mutations.
|
30552700 |
2019 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of Squamous cell carcinomas as a serious adverse event to BRAF inhibition may be caused by similar mechanisms in non BRAF mutated keratinocytes.
|
31261023 |
2019 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vemurafenib, a selective BRAF kinase inhibitor, has been found to induce several cutaneous adverse effects, ranging from a keratosis pilaris-like reaction to squamous cell carcinoma.
|
30474875 |
2019 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the BRAF inhibitors, main cutaneous side effects are photosensitivity, plantar hyperkeratosis, and the appearance of verrucal keratosis or squamous cell carcinoma.
|
29799097 |
2018 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This phenomenon manifests clinically in the development of squamous cell carcinomas (SCCs) and keratoacanthomas (KAs) in patients treated with BRAF inhibitors.
|
28796396 |
2017 |
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Checkpoint inhibitor antibodies have been used for treatment of cutaneous SCC, Merkel cell carcinoma, and MM; epidermal growth factor receptor inhibitors have been used for cutaneous SCC; hedgehog pathway inhibitors have been used for BCC; and BRAF and MEK inhibitors are being used increasingly in the management of MM.
|
28556451 |
2017 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Treatment with selective BRAF or MEK inhibitors is frequently associated with cutaneous toxicities, including squamous cell carcinoma (SCC), papillomas and rash.
|
25788221 |
2015 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, within the BRAF inhibitor-associated group, the lesions designated as KAs and BRAF inhibitor-associated verrucous keratoses had a similar mutational profile (mutations in PIK3CA, APC, and HRAS), which was distinct to that seen in squamous cell carcinomas (FGFR3, CDKN2A, and STK11).
|
26319365 |
2015 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A frequent adverse effect of mutation-specific BRAF inhibitor therapy is the induction of epithelial proliferations including cutaneous squamous cell carcinomas.
|
24943872 |
2014 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations were detected in 26 (1.3%) of 2001 NSCLC cases (25 adenocarcinomas and 1 squamous cell carcinoma).
|
24297085 |
2014 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients treated with BRAF inhibitors (e.g. vemurafenib), a novel targeted therapy for advanced melanoma harbouring certain BRAF mutations, develop numerous adverse cutaneous side effects, including skin tumors such as squamous cell carcinoma or non-malignant verruciform keratinocyte proliferations, termed 'BRAF-inhibitor-associated verrucous keratosis (BAVK) lesions'.
|
24112647 |
2013 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review.
|
23274581 |
2013 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, as reported for other BRAF inhibitors, dabrafenib also induced MAPK pathway activation in wild-type BRAF cells through CRAF (RAF1) signalling, potentially explaining the squamous cell carcinomas and keratoacanthomas arising in patients treated with BRAF inhibitors.
|
23844038 |
2013 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The growth of cutaneous squamous-cell carcinomas is a unique side-effect of BRAF inhibitor therapy that is induced by the paradoxical activation of the MAPK pathway in cells with RAS mutations.
|
23369684 |
2013 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors.
|
22726224 |
2012 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
|
22256804 |
2012 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Novel mutations of the HRAS gene and absence of hotspot mutations of the BRAF genes in oral squamous cell carcinoma in a Greek population.
|
22294102 |
2012 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations were present in 36 ADCs (4.9%) and one SCC (0.3%; P = .001).
|
21825258 |
2011 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
When the genes were divided into three subgroups according to their roles in the signaling cascade, mutations in the EGFR/ERBB2 and KRAS/BRAF genes were more frequent in ACs than in SCCs (p < 0.001 and p = 0.01, respectively).
|
20881644 |
2010 |
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
RKIP expression levels were significantly higher than the corresponding levels of BRAF (p < 0.001), whereas the two genes showed a negative correlation not only in AK and SCC, but in the adjacent phenotypically normal skin tissue, as well.
|
19342899 |
2009 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Archival primary carcinoma tissues (n=258) in uterine cervix consisting cervical adenocarcinomas (n=115) and squamous cell carcinomas (n=143) were evaluated for activating mutations of BRAF and KRAS and promoter hypermethylation of RASSF1A using methylation specific PCR and specific sequence analysis.
|
17360030 |
2007 |
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Mutations of the BRAF gene in squamous cell carcinoma of the head and neck.
|
12879021 |
2003 |